 Ocuphire Pharma Inc NASDAQ: OCUP announced topline results from the second Phase 3 MIRA-3 trial of Nyxol to reverse pharmacologically-induced mydriasis dilation of the pupil. The trial met its primary endpoint, with 58 of subjects study eye treated with Nyxol returning. 